VFA
ALXN

Valeo Financial Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Valeo Financial Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,086
Closed -$778K – 2088
2021
Q1 		$778K Hold
5,086
– – 0.04% 207
2020
Q4 		$795K Buy
5,086
+4,316
+561% +$555K 0.04% 181
2020
Q3 		$88K Sell
770
-36
-4% -$3.88K 0.01% 502
2020
Q2 		$90K Sell
806
-364
-31% -$38.6K 0.01% 536
2020
Q1 		$114K Hold
1,170
– – 0.01% 396
2019
Q4 		$127K Buy
1,170
+500
+75% +$53.5K 0.01% 409
2019
Q3 		$66K Sell
670
-600
-47% -$67.6K 0.01% 526
2019
Q2 		$166K Buy
1,270
+595
+88% +$76.7K 0.02% 322
2019
Q1 		$91K Buy
675
+198
+42% +$24.6K 0.01% 430
2018
Q4 		$46K Sell
477
-208
-30% -$24.6K 0.01% 519
2018
Q3 		$77K Sell
685
-108
-14% -$13.5K 0.01% 465
2018
Q2 		$94K Sell
793
-285
-26% -$33.3K 0.01% 408
2018
Q1 		$120K Hold
1,078
– – 0.02% 331
2017
Q4 		$129K Buy
1,078
+33
+3% +$4.02K 0.02% 297
2017
Q3 		$147K Buy
+1,045
New +$142K 0.03% 236

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.3B AUM 67.69% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Valeo Financial Advisors's ALXN Position: Q2 2021 in Review

Valeo Financial Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 5,086 shares — an estimated $778K sold.

Valeo Financial Advisors first reported a position in ALXN in Q3 2017 and held it in 15 quarters. The position peaked at $795K in Q4 2020. 710 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • Valeo Financial Advisors reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Valeo Financial Advisors sold 5,086 Alexion Pharmaceuticals shares in Q2 2021, an estimated $778K.
  • Valeo Financial Advisors first reported a position in Alexion Pharmaceuticals in Q3 2017 and held it in 15 quarters.
  • Valeo Financial Advisors's Alexion Pharmaceuticals position peaked at $795K in Q4 2020.
  • 710 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Valeo Financial Advisors's 13F filing for Q2 2021, filed 22 Jul 2021.